Long-term functional islet mass and metabolic function after xenoislet transplantation in primates

Transplantation

Volumn 69, Issue 2, 2000, Pages 195-201

  Contreras, Juan L ^a   Eckhoff, Devin E ^a   Cartner, Samuel ^b   Bilbao, Guadalupe ^b   Ricordi, Camillo ^c   Neville Jr , David M ^d   Thomas, Francis T ^a   Thomas, Judith M ^a,b  

^a UAB Department of Surgery   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF MIAMI   (United States)

^d NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; IMMUNOTOXIN; INSULIN; METHYLPREDNISOLONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CONFERENCE PAPER; FOLLOW UP; GLUCOSE BLOOD LEVEL; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HYPOINSULINEMIA; IMMUNOSUPPRESSIVE TREATMENT; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; LONG TERM CARE; MICROEMULSION; MONKEY; MORBIDITY; MORTALITY; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PRIMATE; PRIORITY JOURNAL;

EID: 0034719405     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200001270-00001     Document Type: Conference Paper

References (22)

1. Hering BH, Ricordi C. Islet transplantation for patients with type 1 diabetes. Graft 1998; 2: 12.
2. Kenyon NS, Alejandro R, Ricordi C. Islet transplantation: beyond the paradigms. Diabetes Metab Rev 1996; 12: 361.
3. Smith RM, Mandel TE. Transplantation treatment for diabetes. Immunol Today 1998; 19: 444.
4. Sutherland DER, Gores PF, Hering BH, Wahoff D, Mckeehen DA, Gruessner RWG. Islet transplantation: an update. Diabetes Metab Rev 1996; 12: 137.
5. Weir GC, Bonner-Weir S. Scientific and political impediments to successful islet transplantation. Diabetes 1997; 46: 1247.
6. Alejandro R, Lehemann R, Ricordi C, et al. Long-term function (6 years) of islet allografts in type 1 diabetes. Diabetes 1997; 46: 1983.
7. Luzi L. Metabolic strategies to predict and improve intrahepatic islet graft function. J Mol Med 1999; 77: 49.
8. Shapiro AM, Gallant H, Hao E, et al. Portal vein immunosuppressant levels and islet graft toxicity. Transplant Proc 1998; 59: 817.
9. Contreras JL, Wang PX, Eckhoff DE, et al. Peritransplant tolerance induction with anti-CD3-immunotoxin: a matter of proinflammatory cytokine control. Transplantation 1998; 65: 1159.
10. Knechtle SJ, Vargo D, Fechner J, et al. FN18-CRM9 immunotoxin promotes tolerance in primate renal allografts. Transplantation 1997; 63: 12.
11. Thomas JM, Neville DM Jr, Contreras JL, et al. Preclinical studies of allograft tolerance in rhesus monkeys: a novel anti-CD3-immunotoxin given peritransplant with donor bone marrow induces operational tolerance to kidney allografts. Transplantation 1997; 64: 124.
12. Thomas FT, Ricordi C, Contreras JL, et al. Reversal of naturally occurring diabetes in primates by unmodified islet xenografts without chronic immunosuppression. Transplantation 1999; 67: 846.
13. Neville DM Jr, Sharff J, Hu HZ, et al. A new reagent for the induction of T-cell depletion: anti-CD3-CRM9. J Immunother Emphasis Tumor Immunol 1996; 19: 85.
14. Hansen BC, Bodkin NL. Heterogeneity of insulin responses: phases leading to type 2 (non-insulin-dependent) diabetes mellitus in the rhesus monkey. Diabetologia 1986; 29: 713.
15. McCulloch DK, Koerker DJ, Kahn ST, Bonner-Weir S, Palmer JP Correlations of in vivo β-cell function test with B-cell mass and pancreatic insulin content in streptozotocin-administered baboons. Diabetes 1991; 40: 673.
16. Teuscher AU, Kendall DM, Smets YFC, Leone JP, Sutherland DER Robertson RP. Successful islet autotransplantation in humans: functional insulin secretory reserve as an estimate of surviving islet cell mass. Diabetes 1998; 47: 324.
17. Contreras JL, Eckhoff DE, Cartner S, et al. Tolerability and side effects of anti-CD3-immunotoxin in kidney and pancreatic islet recipients. Transplantation 1999; 68: 215.
18. Sutton R, Gray DWR, Burnett M, McShane P, Turner RC, Morris PJ. Metabolic function of intraportal and intrasplenic islet autografts in cynomolgus monkeys. Diabetes 1989; 38: 182.
19. Sharp DW, Lacy PE, Weide LG, et al. Intraportal islet autografts: the use of stimulation index to represent functional results. Transplant Proc 1991; 23: 796.
20. Jindal RM, Sidner RA, Milgrom ML. Postransplant diabetes mellitus: the role of immunosuppression. Drug Safety 1997; 16: 242.
21. Lehemann R, Kenyon NS, Fernandez L, et al. Prevention of rejection allows for maintenance of islet mass at pre-pancreatectomy levels in Baboon (Papio hamadryas) recipients of islet allografts. Diabetes 1997; 46: A75.
22. Thomas FT, Pittman K, Berzina P, et al. Pancreatic islet xenografts but not allografts are resistant to autoimmune disease recurrence following islet transplantation. Transplant Proc 1997; 29: 760.